COSCIENS Biopharma Inc.
COSCIENS Biopharma Inc.
- Market cap
- $8.58M
Your view on CSCI.TO
Overview
What the company does, where it operates, and who runs it.
About COSCIENS Biopharma Inc.
- Industry
- Medical - Pharmaceuticals
- Sector
- Healthcare
- CEO
- Peter Harry Puccetti
- Headquarters
- 22 Adelaide Street West, Toronto, ON, CA
- Industry
- Medical - Pharmaceuticals
- Sector
- Healthcare
- CEO
- Peter Harry Puccetti
- Headquarters
- 22 Adelaide Street West, Toronto, ON, CA
COSCIENS Biopharma Inc., a life science company, develops and commercializes products for the cosmeceutical, nutraceutical and pharmaceutical markets in the United States, Germany, the United Kingdom, and internationally. It operates through Active Ingredient and Pharmaceutical segments.
The company offers active ingredients comprising oat beta glucan, a functional ingredient that supports overall health and wellness; oat powder and peptides; oat oil which is extracted from whole oat kernels by a gentle process that retains all the important biologically active components; and avenanthramides, a natural-based ingredients used to inflammation-based diseases for the cosmeceutical and pharmaceutical industries.
It also provides Macrilen/Ghryvelin (macimorelin), an orally active peptidomimetic small molecule that stimulates the secretion of growth hormone from the pituitary gland. The company sells its products through its distribution network.
It has license agreements with Pharmanovia, Davimed GmbH, and NK MEDITECH Ltd, as well as Agriculture Canada, Canadian Government, and University of Alberta.
The company was formerly known as Aeterna Zentaris Inc. and changed its name to COSCIENS Biopharma Inc. in August 2024. COSCIENS Biopharma Inc. was incorporated in 1990 and is based in Toronto, Canada.
Stock Data
Price chart, volume, and trading data.
What moved it
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for COSCIENS Biopharma Inc.. Starting points for COSCIENS Biopharma Inc.: EPS -C$6.43, beta 1.80 — an Medical - Pharmaceuticals name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for COSCIENS Biopharma Inc.. Trailing twelve-month EPS for COSCIENS Biopharma Inc. stands at -C$6.43. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Wall Street Analyst Estimates
Analysts' price targets, ratings, and revenue and EPS estimates.
Buy
Analyst ratings
6 ratings- Strong Buy0
- Buy4
- Hold1
- Sell1
- Strong Sell0
Earnings per share estimates
| Per share | This quarterDec 2026 | Next quarterMar 2027 | This yearYear to Dec 2017 | Next yearYear to Dec 2018 |
|---|---|---|---|---|
| Average estimate | −$5.33 | −$5.33 | −$424.09 | $114.34 |
| Lowest estimate | −$5.33 | −$5.33 | −$424.09 | $114.34 |
| Highest estimate | −$5.33 | −$5.33 | −$424.09 | $114.34 |
| Number of analysts | 1 | 1 | 1 | 1 |
| A year ago | −$6.30 | −$2.011 | — | — |
| Growth vs a year ago | +15.4% | — | — | — |
1The year-ago figure includes one-time items, so growth is not shown.
Revenue estimates
| Total | This quarterDec 2026 | Next quarterMar 2027 | This yearYear to Dec 2017 | Next yearYear to Dec 2018 |
|---|---|---|---|---|
| Average estimate | $546056.00 | $546056.00 | $870837.00 | $25.82M |
| Lowest estimate | $546056.00 | $546056.00 | $870837.00 | $25.82M |
| Highest estimate | $546056.00 | $546056.00 | $870837.00 | $25.82M |
| Number of analysts | 1 | 1 | 1 | 1 |
| A year ago | $1.79M | $1.86M | — | — |
| Growth vs a year ago | −69.5% | −70.6% | — | — |
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for COSCIENS Biopharma Inc.. COSCIENS Biopharma Inc. has reported as a listed company since 1996. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
| Ticker | Type | Company | Sector | Exchange | Mkt cap |
|---|---|---|---|---|---|
| ETBIEastgate Biotech Corp. | Healthcare | OTC | $2.1M | ||
| EVAHFEGF Theramed Health Corp. | Healthcare | OTC | $602,324 | ||
| FITXCreative Edge Nutrition, Inc. | Healthcare | OTC | $47,480 | ||
| FSPMFusionPharm, Inc. | Healthcare | OTC | $1,259 | ||
| GCANThe Greater Cannabis Company, Inc. | Healthcare | OTC | $207,059 | ||
| GEATFRadiko Holdings Corp. | Healthcare | OTC | $4,453 | ||
| GEDSFGedeon Richter PLC | Healthcare | OTC | $4.5B | ||
| GHTIG-H-3 International Inc. | Healthcare | OTC | — | ||
| GRPIGrupo International Inc. | Healthcare | OTC | $1,043 | ||
| GSACGelStat Corporation | Healthcare | OTC | $247,192 | ||
| GWLLGoldenwell Biotech, Inc. | Healthcare | OTC | $104.0M | ||
| HADVHealth Advance Inc. | Healthcare | OTC | $48,284 | ||
News
Latest headlines and market coverage.
About this section
Latest headlines and company announcements for COSCIENS Biopharma Inc.. Coverage tracks COSCIENS Biopharma Inc. within Medical - Pharmaceuticals (Healthcare). Press releases and market coverage, newest first.
Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of COSCIENS Biopharma Inc.